Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Gosuranemab Biologics Sequence Review Report 2026: Tau Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gosuranemab, an antibody targeting Tau.
6 min read
Tilavonemab Biologics Sequence Review Report 2026: Tau Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tilavonemab, an antibody targeting Tau.
6 min read
Prasinezumab Biologics Sequence Review Report 2026: α-synuclein Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Prasinezumab, an antibody targeting α-synuclein.
6 min read
Solanezumab Biologics Sequence Review Report 2026: Amyloid-β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solanezumab, an antibody targeting Amyloid-β.
6 min read
Remternetug Biologics Sequence Review Report 2026: Amyloid-β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Remternetug, an antibody targeting Amyloid-β.
6 min read
Gantenerumab Biologics Sequence Review Report 2026: Amyloid-β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gantenerumab, an antibody targeting Amyloid-β.
6 min read
Aducanumab Biologics Sequence Review Report 2026: Amyloid-β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aducanumab, an antibody targeting Amyloid-β.
6 min read
Donanemab Biologics Sequence Review Report 2026: Amyloid-β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Donanemab, an antibody targeting Amyloid-β.
6 min read
Lecanemab Biologics Sequence Review Report 2026: Amyloid-β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lecanemab, an antibody targeting Amyloid-β.
6 min read
Orilanolimab Biologics Sequence Review Report 2026: FcRn Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Orilanolimab, an antibody targeting FcRn.
6 min read
Batoclimab Biologics Sequence Review Report 2026: FcRn Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Batoclimab, an antibody targeting FcRn.
6 min read
Nipocalimab Biologics Sequence Review Report 2026: FcRn Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nipocalimab, an antibody targeting FcRn.